EVA-Pulsar | Left Ventricular Assist Device EVA-Pulsar

Long-term implantable bionic pulsatile LVAD

Registration Certificate Number: National Medical Device Registration Approval 20193120603

Core Technology Path

Hydrodynamic Suspension

Third-generation pure water hydrodynamic suspension technology, immune to magnetic field interference, capable of dry running without blood, non-destructive to blood components.

Bionic Pulsatility

Pulsatile blood flow protects organs, mimics the natural heart, and reduces complications.

Low Speed, High Flow

Daily operating speed 1600-1800rpm, delivering powerful support of up to 20L/min.

Core Advantages

A long-term implantable bionic pulsatile LVAD with a pulsatile blood flow design to mimic the native heart, "sensing" the patient's cardiac contractions and adjusts blood flow accordingly to match physiological demands, delivering safer long-term life support and improved quality of life for heart failure patients.

20 L/min

stable blood flow support capacity

1600-1800 rpm

core operating speed

100 %

clinical trial survival rate (one-year)

25 %

cardiac function recovery

Information and data source: EVAHEART Left Ventricular Assist Device Product Technical Requirements, Chinese Journal of Cardiology

Development History

Full-process layout from technology to clinical application, with a technology update every 1.5 years

2019

EVAHEART Left Ventricular Assist Device received regulatory approval for market launch, becoming China's first approved LVAD product, "marking the entry of China's severe heart failure treatment into the LVAD era."

2019

2022

Globally exclusive patented Bioflow cannula received regulatory approval for market launch

2022

2023

EVA-Pulsar Left Ventricular Assist Device received regulatory approval for market launch

2023

2025

Next-generation smart integrated controller received regulatory approval for market launch, featuring an intelligent integrated architecture with emergency backup battery to prevent accidental disconnection at the source

2025

2026

New Eva next-generation Left Ventricular Assist Device under R&D verification

2026